As of 2025-12-12, the Intrinsic Value of Rubius Therapeutics Inc (RUBY) is -14.47 USD. This RUBY valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.08 USD, the upside of Rubius Therapeutics Inc is -17,533.68%.
Based on its market price of 0.08 USD and our intrinsic valuation, Rubius Therapeutics Inc (RUBY) is overvalued by 17,533.68%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -14.47 - -14.47 | -14.47 | -17,533.68% |
| P/E | (60.48) - (66.39) | (67.86) | -81863.9% |
| DDM - Stable | (16.08) - (36.99) | (26.54) | -32071.4% |
| DDM - Multi | (12.68) - (23.51) | (16.55) | -20045.8% |
| Market Cap (mil) | 5.15 |
| Beta | 4.04 |
| Outstanding shares (mil) | 62.08 |
| Enterprise Value (mil) | -9.75 |
| Market risk premium | 4.60% |
| Cost of Equity | 13.82% |
| Cost of Debt | 5.00% |
| WACC | 8.74% |